FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

Fast Track Given to Alto Bio Bladder Cancer Therapy

FDA grants Altor BioScience a fast track designation for its investigational interleukin-15 agonist complex, ALT-803, in combination with bacillus Cal...

Human Drugs

Biosimilars Forum Seeks Flexible Interchangeability Approach

The Biosimilars Forum urges FDA to be more flexible with its approach in determining a proposed biosimilar products interchangeability with an innovat...

Human Drugs

Wockhardt Grappling with FDA Issues

Wockhardt says expenses to correct issues raised by FDA at several of its facilities adversely affected company profitability in the first quarter.

Medical Devices

Medtronic HeartWare Splice Kit Recall is Class 1: FDA

FDA says Medtronics recall of a HeartWare driveline splice kit due to a design defect that could lead to an interrupted electrical connection to a ven...

Human Drugs

FDA Approves Designations for 3 Additional Sangamo Products

FDA grants special regulatory designations to three additional Sangamo Therapeutics products.

Human Drugs

Apotex Wants Neulasta Biosimilar Requirements

Apotex asks FDA to set specific requirements for biosimilar applicants referencing Amgens Neulasta.

Medical Devices

FDA Clears Interscope EndoRotor System

FDA clears an Interscope 510(k) for the EndoRotor System for use in gastroenterology and colorectal surgery.

Human Drugs

FDA OKs Phase 3 Trial for Soligenixs Dusquetide

FDA gives Soligenix the green light to advance a pivotal Phase 3 clinical trial evaluating SGX942 (dusquetide) for treating oral mucositis in head and...

Human Drugs

IND Approved for ZioPharm CAR-T Therapy in Leukemia Patients

FDA approves an investigator-initiated IND to begin a Phase 1 trial involving ZioPharm Oncologys CD33-specific CAR-T therapy for relapsed or refractor...

Human Drugs

Patient Groups Expanded Access Principles

Seven patient advocacy groups issue principles they want to see followed in any changes to the compassionate use process.